(Metyrapone + oxazepam) is under clinical development by Embera NeuroTherapeutics and currently in Phase II for Substance (Drug) Abuse. According to GlobalData, Phase II drugs for Substance (Drug) Abuse have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Metyrapone + oxazepam)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Metyrapone + oxazepam) overview

EMB-001 is under development for the treatment of tobacco use disorders, eating disorders, gambling disorder, post traumatic stress disorder (PTSD), drug addiction disorders including cocaine, cannabis and methamphetamine addiction. It is administered orally as capsule. The drug candidate is a combination of benzodiazepine oxazepam and the cortisol synthesis inhibitor metyrapone. Oxazepam targets gamma-amino butyric acid (GABA) receptor and metyrapone targets steroid 11 beta-hydroxylase.

Embera NeuroTherapeutics overview

Embera NeuroTherapeutics (Embera) is a clinical-stage pharmaceutical company that discovers and develops new treatments for treating various addictions. The company develops EMB-001, a drug combination for the stress response system and specific brain functions that results in craving and improvement associated with the disorders. It provides preclinical studies, clinical research and clinical trial services. Embera offers products and therapeutics for smoking cessation, cocaine dependence and other addictions. The company operates through other health sciences center to support a cocaine dependence development program. The company operates through its offices in Sudbury and Shreveport. Embera is headquartered in Sudbury, Massachusetts, the US.

For a complete picture of (Metyrapone + oxazepam)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.